Strategies to improve drug delivery in bladder cancer therapy

Bibliography

• Murta-Nascimento C, Schmitz-Dräger BJ, Zeegers MP, et al. Epidemiology of urinary bladder cancer: from tumour development to patient's death. World J Urol 2007;25:285-95
   PubMed Web of Science ®Google Scholar
• Wu X, Ros MM, Gu J, Kiemeney L. Epidemiology and genetic susceptibility to bladder cancer. BJU Int 2008;102:1207-15
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96
   PubMed Web of Science ®Google Scholar
• Colombel M, Soloway M, Akaza H, et al. Epidemiology, staging, grading, and risk stratification of bladder cancer. Eur Urol Suppl 2008;7(10):618-26
   Web of Science ®Google Scholar
• Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66:4-34
   PubMed Web of Science ®Google Scholar
• Shah JB, McKiernan JM. Novel therapeutics in the treatment of bladder cancer. Curr Opin Urol 2004;14:287-93
   PubMed Web of Science ®Google Scholar
• Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997;15:2564-9
   PubMed Web of Science ®Google Scholar
• Duncan R, Connors TA, Meada H. Drug targeting in cancer therapy: the magic bullet, what next? J Drug Target 1996;3:317-9
   PubMed Web of Science ®Google Scholar
• Lewis SA. Everything you wanted to know about the bladder epithelium but were afraid to ask. Am J Physiol Renal Physiol 2000;278:F867-74
   PubMed Web of Science ®Google Scholar
• Witjes JA, Hendricksen K. Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. Eur Urol 2008;53:45-52
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 1989;64:2448-58
   PubMed Web of Science ®Google Scholar
• Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-66
   PubMed Web of Science ®Google Scholar
• Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997;15:2564-9
   PubMed Web of Science ®Google Scholar
• Harker WG, Meyers FJ, Freiha FS, et al. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract; a Northern California Oncology Group Study. J Clin Oncol 1985;3:1463-70
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Albiol S, Suárez C, Albanell J. Optimizing therapeutic strategies in advanced bladder cancer: Update on chemotherapy and the role of targeted agents. Crit Rev Oncol Hematol 2009;69:211-22
   PubMed Web of Science ®Google Scholar
• Wientjes MG, Badalament RA, Au JL. Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer. Cancer Chemother Pharmacol 1993;32:255-62
   PubMed Web of Science ®Google Scholar
• Au JL, Badalament RA, Wientjes MG, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 2001;93:597-604
   PubMed Web of Science ®Google Scholar
• Groos E, Masters JR. Intravesical chemotherapy: studies on the relationship between osmolality and cytotoxicity. J Urol 1986;136:399-402
   PubMed Web of Science ®Google Scholar
• Tyagi P, Li Z, Chancellor M, et al. Sustained intravesical drug delivery using thermosensitive hydrogel. Pharm Res 2004;21:832-7
   PubMed Web of Science ®Google Scholar
• Jeong B, Bae YH, Lee DS, et al. Biodegradable block copolymers as injectable drug-delivery systems. Nature 1997;388:860-2
   PubMed Web of Science ®Google Scholar
• Grabnar I, Bogataj M, Mrhar A. Influence of chitosan and polycarbophil on permeation of a model hydrophilic drug into the urinary bladder wall. Int J Pharm 2003;256:167-73
   PubMed Web of Science ®Google Scholar
• Kos MK, Bogataj M, Veranic P, et al. Permeability of pig urinary bladder wall: time and concentration dependent effect of chitosan. Biol Pharm 2006;29:1685-91
   PubMed Web of Science ®Google Scholar
• Oztürk E, Erog˘lu M, Ozdemir N, et al. Bioadhesive drug carriers for postoperative chemotherapy in bladder cancer. Adv Exp Med Biol 2004;553:231-42
   PubMed Web of Science ®Google Scholar
• Lee SJ, Kim SW, Chung H, et al. Bioadhesive drug delivery system using glyceryl monooleate for the intravesical administration of paclitaxel. Chemotherapy 2005;51:311-8
   PubMed Web of Science ®Google Scholar
• Johnson JW, Nayar R, Killion JJ, et al. Binding of liposomes to human bladder tumor epithelial cell lines: implications for an intravesical drug delivery system for the treatment of bladder cancer. Sel Cancer Ther 1989;5:147-55
   PubMedGoogle Scholar
• Vail DM, Amantea MA, Colbern GT, et al. Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin Oncol 2004;31:16-35
   PubMed Web of Science ®Google Scholar
• Chihara Y, Fujimoto K, Kondo H, et al. Anti-tumor effects of liposome-encapsulated titanium dioxide in nude mice. Pathobiology 2007;74:353-8
   PubMed Web of Science ®Google Scholar
• Homhuan A, Harashima H, Yano I. Cellular attachment and internalization of cationic liposomes containing mycobacterial cell wall. Science Asia 2008;34:179-85
   Google Scholar
• Le Visage C, Rioux-Leclercq N, Haller M, et al. Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer. J Urol 2004;171:1324-9
   PubMed Web of Science ®Google Scholar
• Lu Z, Yeh TK, Tsai M, et al. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin Cancer Res 2004;10:7677-84
   PubMed Web of Science ®Google Scholar
• Vicari L, Musumeci T, Giannone I, et al. Paclitaxel loading in PLGA nansopheres affected the in vitro drug cell accumulation and antiproliferative activity. BMC Cancer 2008;8:212-222
   PubMed Web of Science ®Google Scholar
• Mugabe C, Hadschick BA, Kainthan RK, et al. Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy. BJU Int 2009;103:978-86
   PubMed Web of Science ®Google Scholar
• Bilensoy E, Sarisozen C, Esendag˘li G, et al. Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors. Int J Pharm 2009;371:170-6
   PubMed Web of Science ®Google Scholar
• Hampel S, Kunze D, Haase D, et al. Carbon nanotubes filled with a chemotherapeutic agent: a nanocarrier mediates inhibition of tumor cell growth. Nanomed 2008;3:175-82
   PubMed Web of Science ®Google Scholar
• Schoenfeld RH, Belville WD, Jacob WH, et al. The effect of dimethyl sulfoxide on the uptake of cisplatin from the urinary bladder of the dog: a pilot study. J Am Osteophat Assoc 1983;82:570-3
   PubMedGoogle Scholar
• See WA, Xia Q. Regional chemotherapy for bladder neoplasms using continuous intravesical infusion of doxorubicin: impact of concomitant administration of dimethyl sulfoxide on drug absorption and antitumor activity. J Natl Cancer Inst 1992;84:510-5
   PubMed Web of Science ®Google Scholar
• Hashimoto H, Tokunaka S, Sasaki M, et al. Dimethyl sulfoxide enhances the absorption of chemotherapeutic drug instilled into the bladder. Urol Res 1992;20:233-6
   PubMed Web of Science ®Google Scholar
• Yaman O, Ozdiler E, Sözen S, et al. Transmurally absorbed intravesical chemotherapy with dimethylsulfoxide in an animal model. Int J Urol 1999;6:87-92
   PubMed Web of Science ®Google Scholar
• Chen D, Song D, Wientjes MG, et al. Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel. Clin Cancer Res 2003;9:363-9
   PubMed Web of Science ®Google Scholar
• Sasaki M, Hashimoto H, Yachiku S. Studies on enhancement of drug absorption through the bladder mucosa. Nippon Hinyokika Gakkai Zasshi 1994;85:1353-62
   PubMedGoogle Scholar
• Horn Y, Eidelman A, Walach N, et al. Intravesical chemotherapy of superficial bladder tumors in a controlled trial with cis-platinum versus cis-platinum plus hyaluronidase. J Surg Oncol 1985;28:304-7
   PubMed Web of Science ®Google Scholar
• Maier U, Baumgartner G. Metaphylactic effect of mitomycin C with and without hyaluronidase after transurethral resection of bladder cancer: randomized trial. J Urol 1989;141:529-30
   PubMed Web of Science ®Google Scholar
• Hoebarth K, Maier U, Marberger M. Topical chemoprophylaxis of superficial bladder cancer with mitomycin C and adjuvant hyaluronidase. Eur Urol 1992;21:206-10
   PubMed Web of Science ®Google Scholar
• Lokeshwar VB, Cerwinda WH, Lokeshwar BL. HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion. Cancer Res 2005;65:2243-50
   PubMed Web of Science ®Google Scholar
• Lokeshwar VB, Estrella L, Lopez M, et al. HYAL1-v1, an alternative spliced variant of HYAL1 hyaluronidase: a negative regulator of bladder cancer. Cancer Res 2006;66:11219-27
   PubMed Web of Science ®Google Scholar
• Phipps JB, Padmanabhan RV, Lattin GA. Iontophoretic delivery of model inorganic and drug ions. J Pharm Sci 1989;78:365-9
   PubMed Web of Science ®Google Scholar
• Lugnani F, Mazza G, Cerulli N. Iontophoresis of drugs in the bladder wall: equipment and preliminary studies. Artif Organs 1993;17:8-17
   PubMed Web of Science ®Google Scholar
• Colombo R, Brausi M, Da Pozzo L, et al. Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication. A pilot study on marker lesion. Eur Urol 2001;39:95-100
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Giannantoni A, Stephan RL, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 2003;170:777-82
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Giannantoni A, Giurioli A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 2006;7:43-51
   PubMed Web of Science ®Google Scholar
• Colombo R, Lev A, Da Pozzo LF, et al. A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment. J Urol 1995;153:959-63
   PubMed Web of Science ®Google Scholar
• Colombo R, Da Pozzo LF, Lev A, et al. Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. J Urol 1996;155:1227-32
   PubMed Web of Science ®Google Scholar
• Paroni R, Salonia A, Lev A, et al. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br J Clin Pharmacol 2001;52:273-8
   PubMed Web of Science ®Google Scholar
• Colombo R, Da Pozzo Lf, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 2003;21:4270-6
   PubMed Web of Science ®Google Scholar
• Van der Heijden AG, Kiemeney LA, Gofrit ON, et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 2004;46:65-71
   PubMed Web of Science ®Google Scholar
• Witjes JA, Hendricksen K, Gofrit NO, et al. Intravesical hyperthermia and mitomycin-C for (BCG-refractory) carcinoma in situ of the urinary bladder. Eur Urol Suppl 2007;6:60
   Google Scholar
• Kriegmair M, Baumgartner R, Lumper W, et al. Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer. Br J Urol 1996;77:667-71
   PubMedGoogle Scholar
• Waidelich R, Stepp H, Baumgartner R, et al. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol 2001;165:1904-7
   PubMed Web of Science ®Google Scholar
• Berger A, Steiner H, Stenzl A, et al. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients wich recurrent superficial bladder cancer: a single-center study. Urology 2003;61:338-41
   PubMed Web of Science ®Google Scholar
• French AJ, Datta SN, Allman R, et al. Investigation of sequential mitomycin C and photodynamic therapy in a mitomycin-resistant bladder cancer cell-line model. BJU Int 2004;93:156-61
   PubMed Web of Science ®Google Scholar
• Skyrme RJ, French AJ, Datta SN, et al. A phase-1 study of sequential mitomycin C and 5-aminolaevulinic acid-mediated photodynamic therapy in recurrent superficial bladder carcinoma. BJU Int 2005;95:1206-10
   PubMed Web of Science ®Google Scholar
• Agostinis P, Vantieghem A, Merlevede W, et al. Hypericin in cancer treatment: more light on the way. Int J Biochem Cell Biol 2002;34:221-41
   PubMed Web of Science ®Google Scholar
• Skalkos D, Gioti E, Stalikas CD, et al. Photophysical properties of Hypericum perforatum L. extracts-novel photosensitizers for PDT. J Photochem Photobiol B 2006;82:146-51
   PubMed Web of Science ®Google Scholar
• Derycke ASL, Kamuhabwa A, Gijsens A, et al. Transferrin-conjugated liposome targeting of photosensitizer AlPcS4 to rat bladder carcinoma cells. J Natl Cancer Inst 2004;96:1620-30
   PubMed Web of Science ®Google Scholar
• Buytaert E, Matroule JY, Durinck S, et al. Molecular effectors and modulators of hypericin-mediated cell death in bladder cancer cells. Oncogene 2008;27:1916-29
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70
   PubMed Web of Science ®Google Scholar
• Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990;265:7709-12
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangeling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37
   PubMed Web of Science ®Google Scholar
• Neal DE, Sharples L, Smith K, et al. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 1990;65:1619-25
   PubMed Web of Science ®Google Scholar
• Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erB-2, p53) expression and long-term prognosis. Br J Cancer 1994;69:1120-5
   PubMed Web of Science ®Google Scholar
• Ravery V, Grignon D, Angulo J, et al. Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth and c-erbB2 in the progression of invasive bladder cancer. Urol Res 1997;25:9-17
   PubMed Web of Science ®Google Scholar
• Izawa JI, Slaton JW, Kedar D, et al. Differential expression of progression-related genes in the evaluation of superficial to invasive transitional cell carcinoma of the bladder. Oncol Rep 2001;8:9-15
   PubMed Web of Science ®Google Scholar
• Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999;5:257-65
   PubMed Web of Science ®Google Scholar
• Inoue K, Slaton JW, Perrotte P, et al. Paclitaxel enhances the effectos of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000;6:4874-84
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27
   PubMed Web of Science ®Google Scholar
• Belani CP, Schreeder MT, Steis RG, et al. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. Cancer 2008;113:2512-7
   PubMed Web of Science ®Google Scholar
• Tahara M, Shirao K, Boku N, et al. Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines. Jpn J Clin Oncol 2008;38:762-9
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov: Information on clinical trails and human research studies. Available from: http://www.clinicaltrials.gov
   Google Scholar
• Fry DW. Mechanism of action of erbB tyrosine kinase inhibitor. Exp Cell Res 2003;84:131-9
   Google Scholar
• Nutt JE, Lazarowicz HP, Mellon JK, et al. Gefitnib (« Iressa », ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2. Br J Cancer 2004;90:1679-85
   PubMed Web of Science ®Google Scholar
• Dominguez-Escrig JL, Kelly JK, Neal DE, et al. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res 2004;10:4874-84
   PubMed Web of Science ®Google Scholar
• Philips GK, Halabi S, Sanford BL, et al. A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the cancer and leukaemia group B 90102. BJU Int 2008;101:20-5
   PubMed Web of Science ®Google Scholar
• Katzel JA, Fanucchi MP, Li Z. Recent advances of novel targeted therapy in non-small cell lung cancer. J Haematol Oncol 2009;2:2
   PubMedGoogle Scholar
• Yang JL, Qu XJ, Hayes VM, et al. Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-alpha. BJU Int 2007;99:1539-45
   PubMed Web of Science ®Google Scholar
• Jabobs MA, Wotkowicz C, Baumgart ED, et al. Epidermal growth factor receptor status and the response of bladder carcinoma cells to erlotinib. J Urol 2007;178:1510-4
   PubMed Web of Science ®Google Scholar
• Lipponen P, Eskelin M, Syrjänen S, et al. Use of immunohistochemically demonstrated c-erbB-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder. Eur Urol 1991;20:238-42
   PubMed Web of Science ®Google Scholar
• Underwood M, Bartlett J, Reeves J, et al. C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res 1995;55:2422-30
   PubMed Web of Science ®Google Scholar
• Lönn U, Lönn S, Friberg S, et al. Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res 1995;1:1189-94
   PubMed Web of Science ®Google Scholar
• Jimenez RE, Hussain M, Bianco FJ Jr, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001;7:2440-7
   PubMed Web of Science ®Google Scholar
• Wester K, Sjöström A, de la Torre M, et al. HER-2: a possible target for the therapy of metastatic urinary bladder carcinoma. Acta Oncol 2002;41:282-8
   PubMed Web of Science ®Google Scholar
• Krüger S, Weitsch G, Büttner H, et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer 2002;102:514-8
   PubMed Web of Science ®Google Scholar
• Caner V, Turk NS, Duzcan F, et al. No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinoma. Pathol Oncol Res 2008;14:261-6
   PubMed Web of Science ®Google Scholar
• Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, Paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a mutlicenter phase II National Cancer Institute trial. J Clin Oncol 2007;25:2218-24
   PubMed Web of Science ®Google Scholar
• Matsubara H, Yamada Y, Naruse K, et al. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization. Oncol Rep 2008;19:57-63
   PubMed Web of Science ®Google Scholar
• Wülfing C, Machiel J, Richel D, et al. A single arm, multicenter, open label phase II study of lapatinib as 2L treatment of locally advanced/metastatic transitional cell carcinoma of the urothelial tract. Proc Am Soc Clin Oncol 2005;23:4594
   Web of Science ®Google Scholar
• Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003;3:11-22
   PubMed Web of Science ®Google Scholar
• Dinney CP, McConkey DJ, Millikan RE, et al. Focus on bladder cancer. Cancer Cell 2004;6:111-6
   PubMed Web of Science ®Google Scholar
• Winquist E, Moore MJ, Chi K, et al. A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urol Oncol 2005;23:143-9
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, von der Maase H, Seigne JD, et al. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer 2005;103:2035-41
   PubMed Web of Science ®Google Scholar
• Fasolo A, Sessa C. mTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs 2008;17:1717-34
   PubMed Web of Science ®Google Scholar
• Senderowicz AM. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs 1999;17:313-20
   PubMed Web of Science ®Google Scholar
• Chien M, Astumian M, Liebowitz D, et al. In vitro evaluation of flavopiridol, a novel cell cycle inhibitor in bladder cancer. Cancer Chemother Pharmacol 1999;44:81-7
   PubMed Web of Science ®Google Scholar
• Wirger A, Perabo FG, Burgemeister S, et al. Flavopiridol, an inhibitor of cyclin-dependant kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo. Anticancer Res 2005;25:4341-7
   PubMed Web of Science ®Google Scholar
• Ciechanover A. Intracellular protein degradation from a vague idea through the lysosome and the ubiquitin-proteasome system and on to human diseases and drug targeting: Nobel Lecture, December 8, 2004. Ann NY Acad Sci 2007;1116:1-28
   PubMed Web of Science ®Google Scholar
• Kamat AM, Karashima T, Davis DW, et al. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 2004;3:279-90
   PubMed Web of Science ®Google Scholar
• Cote RJ, Laird PW, Datar RH. Promotor hypermethylation: a new therapeutic target emerges in urothelial cancer. J Clin Oncol 2005;23:2879-81
   PubMed Web of Science ®Google Scholar
• Bender CM, Pao MM, Jones PA. Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 1998;58:95-101
   PubMed Web of Science ®Google Scholar
• Cheng JC, Matsen CB, Gonzales FA, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 2003;95:399-409
   PubMed Web of Science ®Google Scholar
• Zou L, Zhang P, Luo C, et al. shRNA-targeted hTERT suppress cell proliferation of bladder cancer by inhibiting telomerase activity. Cancer Chemother Pharmacol 2006;57:328-34
   PubMed Web of Science ®Google Scholar
• Gao XD, Chen YR. Inhibition of telomerase with human telomerase reverse transcriptase antisense enhances tumor necrosis factor-alpha-induced apoptosis in bladder cancer cells. Chin Med J (Engl) 2007;120:755-60
   PubMed Web of Science ®Google Scholar
• Bilim VN, Tomita Y, Kawasaki T, et al. Variable bcl-2 phenotype in benign and malignant lesions of urothelium. Cancer Lett 1998;128:87-92
   PubMed Web of Science ®Google Scholar
• Bilim V, Kasahara T, Noboru H, et al. Caspase involved synergistic cytotoxicity of bcl-2 antisense oligonucleotides and adriamycin on transitional cancer cells. Cancer Lett 2000;155:191-8
   PubMed Web of Science ®Google Scholar
• Schaaf A, Sagi S, Langbein S, et al. Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides. Urol Oncol 2004;22:188-92
   PubMed Web of Science ®Google Scholar
• Trougakos IP, Gonos ES. Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol 2002;34:1430-48
   PubMed Web of Science ®Google Scholar
• Miyake H, Eto H, Hara I, et al. Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer koTCC-1 cells. J Urol 2004;171:2477-81
   PubMed Web of Science ®Google Scholar
• Fuessel S, Kueppers B, Ning S, et al. Systematic in vitro evaluation of surviving directed antisense oligodeoxynucleotides in bladder cancer cells. J Urol 2004;171:2471-6
   PubMed Web of Science ®Google Scholar
• Ning S, Fuessel S, Kotzsch M, et al. SiRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol 2004;25:1065-71
   PubMed Web of Science ®Google Scholar
• Reznikoff CA, Belair CD, Yeager TR, et al. A molecular genetic model of human bladder cancer pathogenesis. Semin Oncol 1996;23:571-84
   PubMed Web of Science ®Google Scholar
• Kuball J, Wen SF, Leissner J, et al. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J Clin Oncol 2002;20:957-65
   PubMed Web of Science ®Google Scholar
• Pagliaro LC, Keyhani A, Williams D, et al. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol 2003;21:2247-53
   PubMed Web of Science ®Google Scholar
• Pagliaro LC, Keyhani A, Liu B, et al. Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. Urol Oncol 2003;21:456-62
   PubMed Web of Science ®Google Scholar
• Miyake H, Yamanaka K, Muramaki H, et al. Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Neoplasia 2005;7:171-9
   PubMed Web of Science ®Google Scholar
• Fodor I, Timiryasova T, Denes B, et al. Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model. J Urol 2005;173:604-9
   PubMed Web of Science ®Google Scholar
• Xu HJ, Zhou Y, Seigne J, et al. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res 1996;56:2245-9
   PubMed Web of Science ®Google Scholar
• Pirollo K, Rait A, Zhou Q, et al. Tumor-targeting nanocomplex delivery of novel tumor suppressor RB94 chemosensitizes bladder carcinoma cells in vitro and in vivo. Clin Cancer Res 2008;14:2190-8
   PubMed Web of Science ®Google Scholar
• Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008;269:7-17
   PubMed Web of Science ®Google Scholar
• Canes D, Chiang GJ, Billmeyer BR, et al. Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo. Int J Cancer 2005;113:841-8
   PubMed Web of Science ®Google Scholar
• Kelly WK, Richon VM, O'Conner O, et al. Phase I clinical trial of histone deacetylase inhibitor: superoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003;9:3578-88
   PubMed Web of Science ®Google Scholar
• Karam JA, Fan J, Stanfield J, et al. The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy. Int J Cancer 2007;120:1795-802
   PubMed Web of Science ®Google Scholar
• Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002;29:10-14
   PubMed Web of Science ®Google Scholar
• Homsi J, Daud AI. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 2007;14:285-94
   PubMedGoogle Scholar
• Presta M, Dell'Era P, Mitola S. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16:159-78
   PubMed Web of Science ®Google Scholar
• Knowles MA. Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors. Future Oncol 2008;4:71-83
   PubMed Web of Science ®Google Scholar
• Shao ZM, Nguyen M. Angiogenic factors and bladder cancer. Front Biosci 2002;7:33-5
   PubMed Web of Science ®Google Scholar
• Inoue K, Slaton JW, Karashima T, et al. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 2000;6:4866-73
   PubMed Web of Science ®Google Scholar
• Wu W, Shu X, Hovsepyan H, et al. VEGF receptor expression and signaling in human bladder tumors. Oncogene 2003;22:3361-70
   PubMed Web of Science ®Google Scholar
• Inoue K, Slaton JW, Davis DW, et al. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res 2000;6:2635-43
   PubMed Web of Science ®Google Scholar
• Davis DW, Inoue K, Dinney CP, et al. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. Cancer Res 2004;64:4601-10
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Eckhardt SG, Lockridge JA, et al. Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2005;56:329-36
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Jian W, Liu H, et al. Sunitinib malate is active against human urothelium carcinoma and enhances the activity of cisplatin in a preclinical mode. Urol Oncol 2008 In press
   PubMedGoogle Scholar
• Bradley DA, Dunn R, Nanus D, et al. Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design. Clin Genitourin Cancer 2007;5:460-3
   PubMed Web of Science ®Google Scholar
• Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanism of action. Exp Cell Res 2006;312:594-607
   PubMed Web of Science ®Google Scholar
• Du Z, Hou S. The anti-angiogenic activity of human endostatin inhibits the bladder cancer growth and its mechanism. J Urol 2003;170:2000-3
   PubMed Web of Science ®Google Scholar
• Kikuchi E, Menendez S, Ohori M, et al. Inhibition of orthotopic human bladder tumor growth by lentiviral gene transfer of endostatin. Clin Cancer Res 2004;10:1835-42
   PubMed Web of Science ®Google Scholar
• Schmidt A, Sommer F, Reiner M, et al. Differential endostatin binding to bladder, prostate and kidney tumour vessels. BJU Int 2005;95:174-9
   PubMed Web of Science ®Google Scholar
• Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 1990;348:555-7
   PubMed Web of Science ®Google Scholar
• Osawa S, Terashima Y, Kimura G, et al. Antitumor effects of the angiogenesis inhibitor AGM-1470 on rat urinary bladder tumours induced by N-butyl-N-(4-hydroxylbutyl) nitrosamine. BJU Int 1999;83:123-8
   PubMed Web of Science ®Google Scholar
• Inoue K, Chikazawa M, Fukata S, et al. Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder. Clin Cancer Res 2002;8:2389-98
   PubMed Web of Science ®Google Scholar
• Wanibuchi H, Wei M, Salim EI, et al. Inhibition of rat urinary bladder carcinogenesis by the antiangiogenic drug TNP-470. Asian Pac J Cancer Prev 2006;7:101-7
   PubMedGoogle Scholar
• Inoue K, Chikazawa M, Fukata S, et al. Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma. Clin Cancer Res 2003;9:886-99
   PubMed Web of Science ®Google Scholar
• Muramaki M, Miyake H, Hara I, et al. Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and gemcitabine in a human bladder KoTCC-1 model. J Urol 2004;172:1485-9
   PubMed Web of Science ®Google Scholar
• Karashima T, Sweeney P, Kamat A, et al. Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res 2003;9:2786-97
   PubMed Web of Science ®Google Scholar
• Inoue K, Perrotte P, Wood CG, et al. Gene therapy of human bladder cancer in adenovirus-mediated antisense basic fibroblast growth factor. Clin Cancer Res 2000;6:4422-31
   PubMed Web of Science ®Google Scholar
• Martínez-Torrecuadrada J, Cifuentes G, López-Serra P, et al. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation. Clin Cancer Res 2005;11:6280-90
   PubMed Web of Science ®Google Scholar
• Martínez-Torrecuadrada JL, Cheung LH, López-serra P, et al. Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis. Mol Cancer Ther 2008;7:862-73
   PubMed Web of Science ®Google Scholar
• Singhal A, Hakomori S. Molecular changes in carbohydrate antigens associated with cancer. Bioessays 1990;12:223-30
   PubMed Web of Science ®Google Scholar
• Wirth M, Fuchs A, Wolf M, et al. Lectin-mediated drug targeting: preparation, binding characteristics, and antiproliferative activity of wheat germ agglutinin conjugated with doxorubicin on Caco-2 cells. Pharm Res 1998;15:1031-7
   PubMed Web of Science ®Google Scholar
• Gabor F, Bogner E, Weissenboeck A, Wirth M. The lectin-cell interaction and its implication to intestinal lectin-mediated drug delivery. Adv Drug Deliv Rev 2004;56:459-80
   PubMed Web of Science ®Google Scholar
• Plattner VE, Wagner M, Ratzinger G, et al. Targeted drug delivery: binding and uptake of plant lectins using human 5637 bladder cancer cells. Eur J Pharm Biopharm 2008;70:572-6
   PubMed Web of Science ®Google Scholar
• Horiguchi Y, Larchian WA, Kaplinsky R, et al. Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer mode. Gene Ther 2000;7:844-51
   PubMed Web of Science ®Google Scholar
• Larchian WA, Horiguchi Y, Nair SK, et al. Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer. Clin Clancer Res 2000;6:2913-20
   PubMed Web of Science ®Google Scholar
• O'Donnell MA, Luo Y, Hunter SE, et al. Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity. J Urol 2004;171:1330-5
   PubMed Web of Science ®Google Scholar
• Lee C, Chang S, Hsieh D, et al. Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine. J Urol 2004;171:1343-7
   PubMed Web of Science ®Google Scholar
• Loskog AS, Fransson ME, Totterman TT. AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model. Clin Cancer Res 2005;11:8816-21
   PubMed Web of Science ®Google Scholar
• Nagabhushan TL, Maneval DC, Benedict WF, et al. Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer. Cytokine Grwoth Factor Rev 2007;18:389-94
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Raghavan D. Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties. Nat Clin Pract Oncol 2008;5:444-54
   PubMedGoogle Scholar
• Chauvet B, Brewer Y, Felix-Faure C, et al. Concurrent cisplatin and radiotherapy for patients with muscle invasive bladder cancer who are not candidates for radical cystectomy. J Urol 1996;156:1258-62
   PubMed Web of Science ®Google Scholar
• Birkenhake S, Leykamm S, Martus P, et al. Concomitant radiochemotherapy with 5-FU and cisplatin for invasive bladder cancer. Strahlenther Onkol 1999;175:97-101
   PubMed Web of Science ®Google Scholar
• Kragelj B, Zaletel-Kragelj L, Sedmak B, et al. Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer. Radiother Oncol 2005;75:44-7
   PubMed Web of Science ®Google Scholar
• Weiss C, Engehausen DG, Krause FS, et al. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 2007;68:1072-80
   PubMed Web of Science ®Google Scholar
• Wittlinger M, Roedel C, Weiss C, et al. Organ preserving, quadrimodal treatment of T1-2N0M0 bladder cancer: results after transurethral resection and simultaneous radiochemotherapy combined with regional deep hyperthermia. Int J Radiat Oncol Biol Phys 2007;69:314-5
   Google Scholar
• Weiss C, Ott OJ, Wittlinger M. Treatment options for high-risk T1 bladder cancer. Strahlenther Onkol 2008;184:443-9
   PubMed Web of Science ®Google Scholar
• Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006;25:9-34
   PubMed Web of Science ®Google Scholar
• Lee SJ, Cho YH, Park K, et al. Inhibitory effects of the aqueous extract of Magnolia officinalis on the responses of human urinary bladder cancer 5637 cells in vitro and mouse urinary bladder tumors induced by N-Butyl-N-(4-hydroxybutyl) nitrosamine in vivo. Phytother Res 2009;23:20-7
   PubMed Web of Science ®Google Scholar
• Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-92
   PubMed Web of Science ®Google Scholar
• Cardillo MR, Sale P, Di Silverio F. Heat shock protein-90, IL-6 and IL-10 in bladder cancer. Anticancer Res 2000;20:4579-83
   PubMed Web of Science ®Google Scholar
• Soli DB, Chiosis G. Development and application of Hsp90 inhibitors. Drug Discov Today 2008;13:38-43
   PubMed Web of Science ®Google Scholar
• Taldone T, Gozman A, Maharaj R, et al. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 2008;8:370-4
   PubMed Web of Science ®Google Scholar
• Leakakos T, Ji C, Lawson G, et al. Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers. Cancer Chemother Pharmacol 2003;51:445-50
   PubMed Web of Science ®Google Scholar
• Stewart KM, Horton KL, Kelley SO. Cell-penetrating peptides as delivery vehicles for biology and medicine. Org Biomol Chem 2008;6:2242-55
   PubMed Web of Science ®Google Scholar
• Schwarze SR, Ho A, Vocero-Akbani A, et al. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999;285:1569-72
   PubMed Web of Science ®Google Scholar